Evidence map›Paper›PMID 39811390›Full record

ArticlePrzeglad menopauzalny = Menopause review2024

Triple-negative breast cancer patients treated with subcutaneous mastectomy with immediate reconstruction: single institution experience.

Artur Bocian, Paweł Macek, Piotr Kędzierawski

Abstract read
In one paragraph

Article in Przeglad menopauzalny = Menopause review, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Artur BocianOncological Surgery Clinic, The Holycross Cancer Centre, Kielce, Poland.
Paweł MacekScientific Research, Epidemiology and R&D Centre, The Holycross Cancer Centre, Kielce, Poland.
Piotr KędzierawskiJan Kochanowski University Collegium Medicum, Kielce, Poland.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Triple-negative breast cancer (TNBC) accounts for approximately 15-20% of all breast carcinomas. In the last two decades, both nipple-sparing mastectomy (NSM) and skin-sparing mastectomy (SSM) with immediate reconstruction have been used in the surgical management. The aim of our study was to analyze the outcomes of the combined treatment of patients with TNBC treated with NSM or SSM. Material and methods: A total of 114 women with TNBC were enrolled in this study. All diagnostic, therapeutic and follow-up procedures were conducted in one center of the Holycross Cancer Centre in Kielce. In all patients, subcutaneous mastectomy was performed. Overall survival was estimated by the Kaplan-Meier method. The influence of selected prognostic factors on the risk of death was analyzed using the Cox proportional hazards models. Results: The probability of survival at 1, 3, and 5 years was 0.982, 0.894, 0.850, respectively. Based on the 5-factor Cox model, all included features had a significant relationship with the risk of death. In conclusion, the presence of a genetic mutation, adjuvant chemotherapy, complete pathological regression, and the absence of radiotherapy significantly reduced the risk of death. Conclusions: The results of the treatment with subcutaneous mastectomy are good. The early stage of the cancer is associated with a better prognosis. Complete pathological regression after systemic treatment, particularly in patients with BRCA1 mutation, is a good prognostic factor and can help diminish the range of surgery in the axilla region.

Indexed as

combined treatmentsubcutaneous mastectomytriple-negative breast cancer

Identifiers

PMID39811390
PMCPMC11726194

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-SA
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.